Primer pair, gene probe, kit and application of primer pair, gene probe and kit in identification of klebsiella pneumoniae

Through RPA isothermal amplification technology and colloidal gold strip detection, specific primer pairs and gene probes were designed to solve the problems of long time, high cost and complex operation of Klebsiella pneumoniae detection, and achieve rapid, sensitive and high Specific test results are suitable for clinical and research.

CN118957117APending Publication Date: 2024-11-15SHANGHAI YUNZE BIOTECH +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411294350.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The detection methods of Klebsiella pneumoniae in the prior art have problems such as long time, high cost, complex operation, easy to cause pollution and diagnosis lag, and lack fast, sensitive, high specificity, simple operation and low cost detection methods.

Method used

RPA isothermal amplification technology combined with colloidal gold strip detection, specific primer pairs and gene probes were designed, and visual inspection was carried out on the strips after RPA amplification to achieve rapid and accurate identification of Klebsiella pneumoniae.

Benefits of technology

It realizes fast, sensitive, high specificity, convenient operation and low-cost Klebsiella pneumoniae detection, avoids false positives, provides more accurate identification results, and is suitable for clinical and research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118957117A_ABST
    Figure CN118957117A_ABST
Patent Text Reader

Abstract

The invention discloses a primer pair, a gene probe, a kit and application of the primer pair, the gene probe and the kit in identification of klebsiella pneumoniae. Based on an RPA rapid amplification principle, the primer pair, the gene probe and / or the kit are used for carrying out specific amplification on conserved sequence gene segments of the klebsiella pneumoniae, so that accurate identification of the klebsiella pneumoniae is realized. The application method which is more accurate and easier to operate is provided for klebsiella pneumoniae identification, so that more comprehensive and complex klebsiella pneumoniae identification requirements in production, scientific research and identification aspects in multiple fields of biology, medicine, food and the like are met.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of rapid in vitro detection, and specifically relates to a primer pair, a gene probe and a kit and applications thereof in identifying Klebsiella pneumoniae. Background Art

[0002] Klebsiella pneumoniae is one of the common pathogens in the Enterobacteriaceae family. It is a Gram-negative bacterium that is prone to cause bacteremia, urinary tract infection, lower respiratory tract infection and other diseases, especially in individuals with low immunity. Due to limited antibiotic selection and high morbidity and mortality, the mortality rate of infection caused by carbapenem-resistant K. pneumoniae (CRKP) is 30% to 55%. Therefore, early diagnosis of pathogens plays a key role in the diagnosis and treatment of diseases by clinicians. At present, clinical bacterial detection is mainly carried out through paper culture, imaging detection, NGS, drug sensitivity detection, or PCR detection of pathogen genes. These conventional detection methods have long operation time, too high requirements for laboratories, and rely on expensive experimental equipment. In addition, the strain isolation and processing operations are complicated and there is a certain risk of infection, which is not convenient for detection at the grassroots level or on-site. Therefore, it is necessary to develop an efficient, accurate, sensitive, easy-to-operate, and at-anytime monitoring method for the detection and analysis of Klebsiella pneumoniae, which is of great significance for the scientific research and application of Klebsiella pneumoniae.

[0003] RPA isothermal amplification technology, also known as recombinase polymerase amplification technology (RPA), is a new nucleic acid isothermal amplification technology developed by Piepenburg et al. in 2006 using protein recombination and repair involved in cell DNA synthesis. It is known as a nucleic acid detection technology that can replace PCR. RPA technology mainly relies on three enzymes: recombinase that can bind to single-stranded nucleic acids (oligonucleotide primers), single-stranded DNA binding protein (SSB) and strand displacement DNA polymerase. The reaction process of RPA is first that the recombinase binds to the primer to form a protein-DNA complex, and then the protein-DNA complex searches for homologous sequences in double-stranded DNA. Once the primer finds the target homologous sequence, a chain exchange reaction will occur to form and initiate DNA synthesis, and the exponential amplification of the target sequence on the template will be completed within a few minutes. The replaced DNA chain binds to SSB (single-stranded DNA binding protein) to keep the DNA in a single-stranded state and prevent it from being hydrolyzed by nucleases. The mixture of these three enzymes is also active at room temperature, with the optimal reaction temperature at around 39°C. With only a small amount of sample preparation, it can amplify as few as 1-10 DNA copies within 10 minutes. It has the advantages of high sensitivity, selectivity, portability, rapidity, and the ability to perform multiple amplifications.

[0004] The main principle of colloidal gold test strips is to use cellulose acetate membrane as a carrier, utilize the capillary action of the microporous membrane, and slowly transfer the liquid dripped on one end of the membrane strip to the other end, and use the colloidal gold to show the color reaction through the antigen-antibody binding of the streaked line. The biggest feature of this method is that it is simple to operate, fast and rapid, sensitive and accurate, safe and simple, low cost, and does not require professional personnel and instruments and equipment. The negative and positive color development is obvious, and the test results can usually be observed by the naked eye within 3-5 minutes.

[0005] Currently, the traditional methods for identifying Klebsiella pneumoniae include: imaging, histopathology, direct culture, serological methods, drug sensitivity testing, molecular methods, NGS sequencing methods, etc.

[0006] The limitations of these traditional methods for identifying Klebsiella pneumoniae are:

[0007] 1. All of these identification methods require the cultivation of Klebsiella pneumoniae strains, which takes a long time and is prone to contamination during the cultivation process.

[0008] 2. These identification methods can only identify a specific type of strain, and have serious lags in the diagnosis and treatment of diseases (after symptoms appear, the results cannot be known in time).

[0009] 3. Traditional bacterial molecular identification takes a long time (about 1-2 hours) to extract bacterial genomes, and the steps are complicated. Improper operation during the extraction process can easily cause environmental pollution.

[0010] 4. Conventional strain identification is costly and time-consuming, and is inconvenient and costly for clinical patients.

[0011] Therefore, there is an urgent need for a method for identifying Klebsiella pneumoniae that is rapid, sensitive, highly specific, easy to operate and low-cost. Summary of the invention

[0012] In order to solve the technical problem that the prior art lacks a method for identifying Klebsiella pneumoniae that is rapid, sensitive, highly specific, easy to operate and low-cost, the present invention provides a primer pair, a gene probe and a kit and their application in identifying Klebsiella pneumoniae based on RPA isothermal amplification and test strip detection technology.

[0013] The present invention designs a pair of conservative primers and probes in the conservative region of Klebsiella pneumoniae, and uses the RPA amplification method to establish a visual nucleic acid test strip detection technology for Klebsiella pneumoniae. The detection first extracts the genome of the sample, then performs RPA amplification on the extracted sample, and finally drops the RPA-amplified sample onto the test strip, and the development of the test strip indicates whether the strain exists in the sample.

[0014] In a first aspect, the present invention provides a primer pair for specific amplification of Klebsiella pneumoniae, the primer pair comprising a forward primer and a reverse primer, the nucleotide sequence of the forward primer is shown in any one of SEQ ID NOs: 1-3, and the nucleotide sequence of the reverse primer is shown in any one of SEQ ID NOs: 4-6;

[0015] Preferably, the nucleotide sequence of the forward primer is shown in SEQ ID NO:1, and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:5; or, the nucleotide sequence of the forward primer is shown in SEQ ID NO:2, and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:4; or, the nucleotide sequence of the forward primer is shown in SEQ ID NO:2, and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:5; or, the nucleotide sequence of the forward primer is shown in SEQ ID NO:3, and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:5;

[0016] And / or, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.

[0017] The second aspect of the present invention provides a gene probe coupled with digoxigenin labeling, the nucleotide sequence of the gene probe is shown in SEQ ID NO:8.

[0018] The third aspect of the present invention provides a primer-probe combination, wherein the primer-probe combination comprises the primer pair as described in the first aspect of the present invention and / or the gene probe as described in the second aspect of the present invention;

[0019] Preferably, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is as shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is as shown in SEQ ID NO:4, and a gene probe whose nucleotide sequence is as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is as shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is as shown in SEQ ID NO:5, and a gene probe whose nucleotide sequence is as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is as shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is as shown in SEQ ID NO:6, and a gene probe whose nucleotide sequence is as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is as shown in SEQ ID NO:2 and whose nucleotide sequence of the reverse primer is as shown in SEQ ID NO:4, and a gene probe whose nucleotide sequence is as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is as shown in SEQ ID NO:2 and whose nucleotide sequence of the reverse primer is as shown in SEQ ID NO:4 NO:5, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:2 and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:6, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:3 and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:4, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:3 and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:5, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:3 and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:6, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:8;

[0020] More preferably, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.

[0021] A fourth aspect of the present invention provides a test strip, the test strip comprising a sample pad, a conjugation pad, a nitrocellulose membrane and an absorption pad, the conjugation pad comprising microsphere solution 1 and microsphere solution 2; the nitrocellulose membrane comprising a detection line T line and a quality control line C line;

[0022] The microsphere solution 1 contains microspheres labeled with streptavidin; the microsphere solution 2 contains microspheres labeled with mouse anti-human antibody; the detection line T contains digoxigenin antibody, and the quality control line C contains goat anti-mouse antibody;

[0023] In some preferred embodiments, the test strip meets one or more of the following conditions:

[0024] (1) The particle size of the microspheres is 100-300 nm, for example, 200 nm;

[0025] (2) the molar concentration ratio of streptavidin in the microsphere solution 1 to the digoxigenin antibody in the detection line T is 1:1; and,

[0026] (3) The binding pad is a colloidal gold binding pad, and the amount of gold sprayed onto the microspheres is, for example, 6 μl / cm.

[0027] In the present invention, the detection line T has digoxin antibody, and the quality control line C has goat anti-mouse antibody; there are two kinds of microspheres on the colloidal gold binding pad: one is a microsphere labeled with streptavidin (SA), and the other is a microsphere labeled with mouse anti-human antibody. When the test strip is used for sample detection, since the amplified positive sample is labeled with biotin and digoxin, the sample is added to the glass fiber sample pad and flows to the colloidal gold binding pad. At this time, biotin will bind to the microspheres labeled with SA to generate a "microsphere-SA-biotin-positive fragment-digoxin" complex, which will reach the detection line T line along the flow direction. At this time, the complex will bind to the digoxin antibody and intercept the complex at the detection line T line, so the positive fragment will be colored on the detection line T line; if there is no positive fragment in the sample, the complex will not be formed, so the band will not appear on the detection line T line; another microsphere on the colloidal gold binding pad is a mouse anti-human microsphere, which will flow forward with the addition of the sample and will not react with the digoxin antibody on the detection line T line, but will continue to flow forward to the quality control line C line, react with the goat anti-mouse antibody on the quality control line C line, and the microsphere will be intercepted and colored at the quality control line C line.

[0028] The fifth aspect of the present invention provides a use of the primer pair as described in the first aspect of the present invention, the gene probe as described in the second aspect of the present invention, the primer-probe combination as described in the third aspect of the present invention and / or the test strip as described in the fourth aspect of the present invention in the preparation of a kit for identifying Klebsiella pneumoniae.

[0029] The sixth aspect of the present invention provides a kit for identifying Klebsiella pneumoniae, wherein the kit is selected from one or more of the primer pair described in the first aspect of the present invention, the gene probe described in the second aspect of the present invention, the primer-probe combination described in the third aspect of the present invention, and the test strip described in the fourth aspect of the present invention;

[0030] In some preferred embodiments, the kit further comprises a nucleic acid extraction reagent and / or a sample release buffer; the nucleic acid extraction reagent is an alkaline reagent, and the sample release buffer comprises a phosphate buffered saline solution.

[0031] In some more preferred embodiments, the nucleic acid extraction reagent is KOH and / or the sample release buffer is PBST+0.05% Triton.

[0032] In some embodiments, the method for preparing the test strip comprises the following steps:

[0033] i) preparing microsphere solution 1 and microsphere solution 2;

[0034] ii) The test strip is sprayed with gold film.

[0035] In some embodiments, the preparation of the microsphere solution 1 and the microsphere solution 2 in i) specifically comprises the following steps:

[0036] a) Mix the two tubes of microspheres with a particle size of 100-300 nm and the activation buffer in a volume ratio of 1:7;

[0037] b) Add streptavidin to the first tube at a final concentration of 0.1 to 0.15 mg / mL; add mouse anti-human antibody to the second tube at a final concentration of 0.1 to 0.15 mg / mL;

[0038] c) adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide at a final concentration of 1-10 mg / mL to the two tubes of solution in b) respectively, placing the mixture on a constant temperature shaker at a speed of 80-120 rpm and a temperature of 22-26° C. for reaction for 50-70 minutes;

[0039] d) After the reaction is completed, ultrasonicate, add blocking agents respectively, ultrasonicate, and continue to place in a constant temperature shaker at a speed of 80 to 120 rpm and a temperature of 22 to 26° C. for blocking, and the blocking time is 80 to 100 minutes;

[0040] e) After blocking, centrifuge for 20 minutes, discard the supernatant, resuspend the precipitates in the first tube and the second tube with PBS to obtain microsphere solution 1 and microsphere solution 2, and store them in a refrigerator at 2-8°C for later use.

[0041] In some preferred embodiments, the particle size of the microspheres is 200 nm; the activation buffer is a HEPES solution; the final concentration of streptavidin is 0.125 mg / mL; the final concentration of the mouse anti-human antibody is 0.125 mg / mL; the final concentration of 1-ethyl-(3-dimethylaminopropyl)carbodiimide is 1 mg / mL; the blocking agent is a CE510 solution; the rotation speed is 100 rpm, the temperature is 24°C, the reaction time is 60 mins; and the blocking time is 90 mins.

[0042] In some more preferred embodiments, the HEPES solution has a concentration of 5.6 g / L and a pH of 7.45.

[0043] In some embodiments, the test strip gold-sprayed film in ii) specifically comprises the following steps:

[0044] (1) diluting the microsphere solution 1 and the microsphere solution 2 prepared in step (i) by 15 to 25 times with a PBS solution;

[0045] (2) first spraying the diluted microsphere solution 1 of (1) onto the test strip at a concentration of 5 to 7 μl / cm, and drying; then spraying the diluted microsphere solution 2 of (1) onto the test strip at a concentration of 5 to 7 μl / cm, and drying;

[0046] (3) Using a film-spraying gold sprayer, digoxin antigen protein is sprayed on the nitrocellulose membrane as the detection line T line, and goat anti-mouse antibody is sprayed as the quality control line C line to obtain a test strip.

[0047] In some preferred embodiments, the dilution is 20-fold; and the concentration is 6 μl / cm.

[0048] The seventh aspect of the present invention provides a method for identifying Klebsiella pneumoniae in a sample for non-diagnostic purposes, the method comprising using the primer pair as described in the first aspect of the present invention, the gene probe as described in the second aspect of the present invention, the primer-probe combination as described in the third aspect of the present invention, the test strip as described in the fourth aspect of the present invention and / or the kit as described in the sixth aspect of the present invention;

[0049] In some preferred embodiments, the method comprises the following steps:

[0050] (I) performing RPA amplification on the DNA extracted from the sample to be tested using the primer pair described in the first aspect of the present invention, the gene probe described in the second aspect of the present invention, and / or the primer-probe combination described in the third aspect of the present invention to obtain an RPA amplification product; and,

[0051] (II) mixing the RPA amplification product and the sample release buffer in a volume ratio of 1:5, and adding the mixture to the test strip according to the fourth aspect of the present invention;

[0052] In some more preferred embodiments, the method further comprises:

[0053] (III) determining whether Klebsiella pneumoniae is present in the sample to be tested based on the information on the test strip obtained after implementing step (II);

[0054] The judgment conditions are: when the test strip has a detection line T line and a quality control line C line, it means that the result is positive and Klebsiella pneumoniae is present in the sample to be tested; when the test strip has only a quality control line C line but no detection line T line, it means that the result is negative and Klebsiella pneumoniae is not present in the sample to be tested; when the test strip has no quality control line C line, the result is invalid.

[0055] In some embodiments, the DNA sample is obtained by a nucleic acid extraction reagent (alkaline reagent, such as KOH or NaOH).

[0056] In some embodiments, the nucleic acid extraction reagent is 0.1 M KOH.

[0057] In the present invention, "non-diagnostic purpose" application scenarios include, for example, detecting Klebsiella pneumoniae in the environment, detecting Klebsiella pneumoniae on the surface of contact lenses, etc.

[0058] An eighth aspect of the present invention provides an identification system for Klebsiella pneumoniae, the identification system comprising:

[0059] (1) an information collection module: used to collect information on the test strip obtained after using the method according to the seventh aspect of the present invention; and,

[0060] (2) Identification module: used to determine whether the sample to be tested contains Klebsiella pneumoniae; the judgment criteria are:

[0061] a. If there is no quality control line C, the identification result is considered invalid; if there is a quality control line C, proceed to step b;

[0062] b. If there is a T line, it is judged as positive for Klebsiella pneumoniae; if there is no T line, it is judged as negative for Klebsiella pneumoniae;

[0063] (3) Data storage module: used to store user information, detection time, judgment results and other information, which includes user information, detection time and / or judgment results to facilitate the subsequent recording and tracking of pathogen infection information.

[0064] A ninth aspect of the present invention provides a computer-readable storage medium having a computer program stored thereon, wherein the computer program implements the identification system as described in the eighth aspect of the present invention.

[0065] The tenth aspect of the present invention provides an electronic device comprising a memory, a processor and a computer program stored in the memory and executable on the processor, wherein the processor implements the identification system as described in the eighth aspect of the present invention when executing the computer program.

[0066] The eleventh aspect of the present invention provides a use of the primer pair as described in the first aspect of the present invention, the gene probe as described in the second aspect of the present invention, the primer-probe combination as described in the third aspect of the present invention, the test strip as described in the fourth aspect of the present invention, the kit as described in the sixth aspect of the present invention, the identification system as described in the eighth aspect of the present invention, the computer-readable storage medium as described in the ninth aspect of the present invention and / or the electronic device as described in the tenth aspect of the present invention in identifying whether a sample contains Klebsiella pneumoniae.

[0067] In some embodiments, the application is for non-diagnostic purposes, such as detecting Klebsiella pneumoniae in the environment, detecting Klebsiella pneumoniae on the surface of contact lenses, etc.

[0068] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0069] The reagents and raw materials used in the present invention are commercially available.

[0070] The positive and progressive effects of the present invention are:

[0071] The present application designs specific RPA amplification primers and gene probes for the conserved sequence gene fragments of Klebsiella pneumoniae, and can perform RPA amplification identification on all types of Klebsiella pneumoniae. Utilizing the specific amplification primers and gene probes of the present invention, the false positive phenomenon caused by the generation of primer dimers during the RPA amplification process can be effectively avoided, so that the identification result is more accurate. It has the advantages of being fast, sensitive, highly specific, easy to operate, and low in cost. The present invention proposes a Klebsiella pneumoniae identification method and system, which can more conveniently, quickly and accurately identify the type of Klebsiella pneumoniae, is conducive to the identification and research of Klebsiella pneumoniae, and provides substantial reference suggestions for clinical diagnosis and treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0072] Figure 1The figure is the gel electrophoresis diagram of nucleic acid extraction from different strains using different alkaline reagents; M is Marker; NC is negative control; the order of samples is: 1, Staphylococcus aureus; 2, Pseudomonas aeruginosa; 3, Acinetobacter baumannii; 4, Klebsiella pneumoniae; 5, Rhizopus oryzae; 6, Mucor circinelloides.

[0073] Figure 2 The effect of adding specific probes on the detection results.

[0074] Figure 3 Initial screening results for the optimization of primer pairs for Klebsiella pneumoniae amplification; sample order: 1, 1 ng / μl; 2, 0.1 ng / μl; 3, 0.01 ng / μl; the blue line represents ⑤KP-DC-F2 / KP-DC-R2 / KP-DC-PR primer-probe pair combination; the red line represents ②KP-DC-F1 / KP-DC-R2 / KP-DC-PR primer-probe combination; the pink line represents ④KP-DC-F2 / KP-DC-R1 / KP-DC-PR; the green line represents ⑧KP-DC-F / KP-DC-R2 / KP-DC-PR.

[0075] Figure 4 The test strip screening results; the sequence of primer-probe combination is:

[0076] 1. KP-DC-F1 / KP-DC-R2 / KP-DC-PR2;

[0077] 2. KP-DC-F2 / KP-DC-R1 / KP-DC-PR2;

[0078] 3. KP-DC-F2 / KP-DC-R2 / KP-DC-PR2;

[0079] 4. KP-DC-F / KP-DC-R2 / KP-DC-PR2.

[0080] Figure 5 The figure is the gel electrophoresis diagram of the detection results of different markers; lanes 1-8 are: 1. RPA product labeled with digoxigenin; 2. RPA product labeled with digoxigenin combined with digoxigenin antibody-5; 3. RPA product labeled with digoxigenin combined with digoxigenin antibody-6; 4. PCR product labeled with digoxigenin combined with digoxigenin antibody-12; 5. RPA product labeled with digoxigenin combined with digoxigenin antibody-13; 6. RPA product labeled with digoxigenin combined with digoxigenin antibody-14; 7. RPA product labeled with FITC; 8. RPA product labeled with FITC combined with FITC antibody.

[0081] Figure 6For the selection of biotin and digoxigenin labeling concentrations; lanes 1-8 are: 1. RPA product labeled with biotin and digoxigenin (labeled product); 2. Labeled product: SA=4:1; 3. Labeled product: SA=2:1; 4. Labeled product: SA=1:1; 5. Labeled product: SA=1:2; 6. Labeled product: DIG-13=4:1; 7. Labeled product: DIG-13=2:1; 8. Labeled product: DIG-13=1:1.

[0082] Figure 7 Optimization of the sample release buffer.

[0083] Figure 8 Specific detection of test strips for different strain samples.

[0084] Fig. 9 The results of the primer sensitivity test strip test. Lane 1: 1.5*10 7 CFU / ml; Lane 2: 1.5*10 6 CFU / ml; Lane 3: 1.5*10 5 CFU / ml; Lane 4: 1.5*10 4 CFU / ml; Lane 5: 1.5*10 3 CFU / ml; Lane 6: 1.5*10 2 CFU / ml; Lane 7: sterile water.

[0085] Fig.10 Schematic diagram of the identification system for microbial species.

[0086] Fig.11 A schematic diagram of the structure of an electronic device. DETAILED DESCRIPTION

[0087] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0088] Example 1 Sample nucleic acid extraction method

[0089] First, the present invention provides a method for rapidly extracting a genome DNA sample of Klebsiella pneumoniae. The steps of extracting a Klebsiella pneumoniae sample with a sample release agent are as follows: taking 20 μl of the sample, adding 95 μl of 0.1M KOH, 0.5mM EDTA, and vortexing to mix; placing in a 90°C metal bath for incubation for 5 minutes; then standing at room temperature to restore the temperature to room temperature, a flocculent precipitate is precipitated, placing in a centrifuge at 10000rpm for 2 minutes, taking the supernatant and adding a sample preservation solution (Tris-HCl buffer, pH 8.0, 20 μl) to obtain an extracted genome solution.

[0090] The sample crude extraction method was tested for fungi, Gram-positive bacteria, and Gram-negative strains. For the selection of alkaline reagents, 0.1M sodium hydroxide (NaOH) and 0.1M potassium hydroxide (KOH) were selected as the test reagents, and the remaining steps were consistent with the sample release agent treatment method for Klebsiella pneumoniae. PCR amplification verification was performed on the extracted Klebsiella pneumoniae sample DNA. The Klebsiella pneumoniae-specific amplification primers and probe sequences are shown in Table 3; for the primer pair for bacterial verification, 16sDNA-F / R (see Table 3) was selected, and for the primer pair for fungal verification, ITS1 / ITS4 primer pair (see Table 3) was selected. The PCR amplification system and amplification procedure are shown in Tables 1 and 2:

[0091] Table 1 PCR amplification system

[0092]

[0093] Table 2 PCR amplification program

[0094]

[0095] PCR amplification results are shown in Figure 1 .Depend on Figure 1 It can be seen that the selection of potassium hydroxide (KOH) as the alkaline hydrolysis agent in the lysis reagent can play a significant role in the extraction.

[0096] Example 2 Addition of probes to the system

[0097] For the traditional RPA amplification combined with test strip detection method, only a pair of labeled forward and reverse primers need to be designed, but primer dimers will be generated, resulting in false positive test results. This method adds a labeled specific probe (SEQ ID NO: 8) to the RPA amplification system, which can make primer dimers unable to be detected in the test strip.

[0098] Specific results such as Figure 2 As shown: When the probe is added, the T line of NC in the amplification system does not appear, and if the probe is not added, the primer dimers that appear will bind to the T line and cause a false positive.

[0099] Example 3 Optimization and screening of primer pairs for RPA amplification of Klebsiella pneumoniae

[0100] The present invention provides a Klebsiella pneumoniae specific amplification primer pair sequence including: SEQ ID NO: 1-6, wherein the fragment size of the product amplified by the primer pair sequence is about 168 bp. SEQ ID NO: 7-8 are probe sequences, and the sequence information is shown in Table 3:

[0101] Table 3 Amplification primer pairs and probe sequences

[0102]

[0103] Note: 1. "F", "R" and "PR" in the primer names represent the upstream, downstream and probe sequences of the primers respectively.

[0104] 2. FAM-dT is the FAM labeling group, DIG-dT is the DIG labeling group, BHQ1-dT is the BHQ1 labeling group, THF is the tetrahydrofuran molecule, and C3-spacer is the blocking group at the 3' end. The 5' end of the reverse primer (KP-DC-R1, KP-DC-R2, KP-DC-R) is labeled with Biotin.

[0105] 3. The sequences of the two fluorescent probes KP-DC-PR and KP-DC-PR2 are the same, but the labels are different. KP-DC-PR is for use in fluorescence screening and is labeled with FAM fluorescent signal and BHQ1 quenching group; KP-DC-PR2 is for screening and detection on test strips and is labeled with DIG antibody.

[0106] 3.1 Fluorescence screening

[0107] (1) According to the arranged sample sequence, the corresponding samples are marked on the PCR reaction 96-well plate (i.e., reaction plate, whose naming rule is "experiment date-sample label-site information") or 200 μl reaction tube of the biotechnology. The Klebsiella pneumoniae (ATCC700603) bacterial liquid samples are transferred from the sample tube in sequence with a pipette. The nucleic acid samples of the Klebsiella pneumoniae liquid are extracted according to the nucleic acid extraction method optimized in Example 1. The nucleic acid sample should be added to the bottom of the reaction well; if the sample is not added to the bottom of the reaction well during the sample addition process, it should be centrifuged briefly after the sample addition is completed, and the extracted Klebsiella pneumoniae genomic DNA product is obtained after the reaction is completed. The samples used in the screening process are: 1 ng / μl, 0.1 ng / μl, 0.01 ng / μl, and sterile water (NC) extracted from Klebsiella pneumoniae. These four samples are screened and tested.

[0108] (2) Amplification was performed using the primer-probe combinations in Table 3, ①KP-DC-F1 / KP-DC-R1 / KP-DC-PR, ②KP-DC-F1 / KP-DC-R2 / KP-DC-PR, ③KP-DC-F1 / KP-DC-R / KP-DC-PR, ④KP-DC-F2 / KP-DC-R1 / KP-DC-PR, ⑤KP-DC-F2 / KP-DC-R2 / KP-DC-PR, ⑥KP-DC-F2 / KP-DC-R / KP-DC-PR, ⑦KP-DC-F / KP-DC-R1 / KP-DC-PR, ⑧KP-DC-F / KP-DC-R2 / KP-DC-PR, and ⑨KP-DC-F / KP-DC-R / KP-DC-PR.

[0109] (3) Configure the RPA reaction system according to Table 4:

[0110] Table 4 RPA reaction system

[0111]

[0112]

[0113] After the system is configured as above, vortex mix, add 2.5 μl of the activator in the DNA constant temperature rapid amplification kit, vortex mix, and place in the ABI7300 real-time fluorescence quantitative PCR reaction instrument for constant temperature reaction at 39°C for 20 minutes.

[0114] (4) Fluorescence curve results are as follows Figure 3 shown.

[0115] Figure 3 In the figure, the blue line represents ⑤KP-DC-F2 / KP-DC-R2 / KP-DC-PR primer-probe pair combination; the red line represents ②KP-DC-F1 / KP-DC-R2 / KP-DC-PR primer-probe combination; the pink line represents ④KP-DC-F2 / KP-DC-R1 / KP-DC-PR; the green line represents ⑧KP-DC-F / KP-DC-R2 / KP-DC-PR; the gray line represents other non-target screening primer-probe combinations.

[0116] Different primer-probe combinations were screened, among which: ②KP-DC-F1 / KP-DC-R2 / KP-DC-PR; ④KP-DC-F2 / KP-DC-R1 / KP-DC-PR; ⑤KP-DC-F2 / KP-DC-R2 / KP-DC-PR; ⑧KP-DC-F / KP-DC-R2 / KP-DC-PR had shorter signal values ​​and reaction threshold time, and higher signal values ​​than other groups. Therefore, these four pairs of primer-probes were selected for further testing.

[0117] 3.2 Test strip screening

[0118] (1) According to the arranged sample sequence, the corresponding samples are marked on the PCR reaction 96-well plate (i.e., reaction plate, whose naming rule is "experiment date-sample label-site information") or 200 μl reaction tube of the biotechnology. Use a pipette to transfer the Klebsiella pneumoniae (ATCC700603) bacterial liquid samples from the sample tube in sequence. The Klebsiella pneumoniae liquid samples are extracted according to the above-mentioned optimized extraction method. The sample should be added to the bottom of the reaction well; if the sample is not added to the bottom of the reaction well during the addition process, it should be centrifuged briefly after the addition is completed. After the reaction is completed, the extracted Klebsiella pneumoniae genomic DNA product is obtained. The samples used in the screening process are: 0.01 ng / μl, 1 pg / μl, 0.1 pg / μl, and sterile water (NC) extracted from Klebsiella pneumoniae. These four samples are screened and tested.

[0119] (2) Use primer-probe combinations, ② KP-DC-F1 / KP-DC-R2 / KP-DC-PR2;

[0120] ④KP-DC-F2 / KP-DC-R1 / KP-DC-PR2; ⑤KP-DC-F2 / KP-DC-R2 / KP-DC-PR2; ⑧KP-DC-F / KP-DC-R2 / KP-DC-PR2 for amplification.

[0121] (3) Prepare the RPA reaction system according to Table 5:

[0122] Table 5 RPA reaction system

[0123]

[0124] After configuring the system as above, vortex mix, add 2.5 μl of the activator in the DNA constant temperature rapid amplification kit, vortex mix, and incubate in a 39°C constant temperature bath for 10 minutes.

[0125] (4) For test strip detection: Take 15 μl of the amplified product and add it to 75 μl of sample buffer. Vortex to mix well and then add it to the treated test strip. Wait for about 3 minutes to determine whether it is positive or negative.

[0126] result Figure 4 As shown. Figure 4It can be seen that for the third pair of primer-probe combinations, samples with a detection sample concentration of 0.1 pg / μl can also be detected, while the sensitivity of the remaining primer-probe combinations is not as good as that of the third pair of primer-probe combinations. Therefore, the primer-probe combination ⑤ KP-DC-F2 / KP-DC-R2 / KP-DC-PR2 is more obvious for the identification result. For low-concentration samples, the primer-probe combination with poor amplification efficiency may not amplify the target band, while the primer-probe combination with high amplification efficiency can amplify the target band, thus proving that the primer-probe combination provided by the present invention can improve the sensitivity of detection.

[0127] Example 4 Preparation of digoxin antibody and FITC antibody

[0128] The following homemade antibodies are for cost considerations, and it is not necessary to use the homemade antibodies of the present invention. Those skilled in the art can prepare antibodies according to conventional methods, such as by the following subclone screening, hybridoma cells are inoculated into mice to collect ascites, and the method of purifying ascites is prepared and screened to obtain the target antibody with good specificity. Alternatively, conventional commercially available digoxin antibodies and FITC antibodies can also be selected. As long as the antibody used can produce a polymer binding with the RPA amplification product with the corresponding antigen marker, the technical effect of the present invention can be achieved.

[0129] The monoclonal antibody used in the example was developed on Balb / c mice using digoxin-BSA complex (Shanghai Maiye Biotechnology Co., Ltd., catalog number: Digoxin-BSA 230510#) as an immunogen. The first intradermal immunization was performed using digoxin-BSA complex (100 μg, as an immunogen) in 100 μl emulsion prepared with Freund's complete adjuvant, and 25 days later, 100 μg of immunogen in 100 μl emulsion prepared with Freund's incomplete adjuvant was used for enhanced immunization. Then, 50 μg of immunogen was used for intradermal immunization twice, with an interval of 4 weeks, and then 50 μg of immunogen was used in 100 μl Hanks balanced salt solution (China Bishi Biotechnology Co., Ltd.) for intravenous and intraperitoneal prefusion promotion (the IgG1 antibody strain in the example was obtained by fusion at the first immunization). Hybridoma cell lines secreting digoxin-specific antibodies were generated using standard fusion technology. After extensive screening, several anti-digoxin antibody clones with good specificity were selected for the development of rapid detection and screening of Klebsiella pneumoniae.

[0130] Antibody subtype testing: A commercially available antibody subtype identification kit (ELISA) was used to identify the subtypes of several digoxin-specific antibodies that were screened. The identification results are shown in Table 6:

[0131] Table 6 Anti-digoxin antibody subtype identification results

[0132]

[0133] The monoclonal antibody used in the example was developed on Balb / c mice using FITC-OVA complex (Shanghai Maiye Biotechnology Co., Ltd., catalog number: FITC-OVA 240206#) as an immunogen. The first intradermal immunization was performed with FITC-OVA complex (100 μg, as an immunogen) in 100 μl emulsion prepared with Freund's complete adjuvant, and 25 days later, 100 μg of immunogen in 100 μl emulsion prepared with Freund's incomplete adjuvant was used for enhanced immunization. Then, 50 μg of immunogen was used for intradermal immunization twice, with an interval of 4 weeks, and then 50 μg of immunogen was used for intravenous and intraperitoneal prefusion promotion in 100 μl Hanks balanced salt solution (China Bishi Biotechnology Co., Ltd.) (the IgG1 antibody strain in the example was obtained by fusion at the first immunization). Hybridoma cell lines secreting digoxin-specific antibodies were generated using standard fusion technology. After extensive screening, anti-FITC antibody clones with good specificity were selected for the development of rapid detection of Klebsiella pneumoniae.

[0134] Antibody subtype testing: The commercially available antibody subtype identification kit (ELISA) was used to identify the subtype FITC-6 of the screened anti-FITC specific antibodies. The identification results are shown in Table 7:

[0135] Table 7 Identification results of anti-FITC antibody subtype FITC-6

[0136]

[0137] Example 5 Screening of markers and antibodies thereof

[0138] In this example, Pseudomonas aeruginosa was used as an example to test the markers and antibodies. The primers for Pseudomonas aeruginosa (PA-lasB-F3 / R3) are shown in Table 8. We selected two markers, digoxin (DIG) and fluorescein isothiocyanate (FITC), and marked them on the reverse primer (PA-lasB-R3) for performance comparison and identification. The amplification method is consistent with the PCR amplification system amplification detection method for detecting Klebsiella pneumoniae in Table 1 described in Example 1. The amplified PCR products labeled with digoxin were incubated with digoxin antibodies (digoxin antibody-5, digoxin antibody-6, digoxin antibody 12, digoxin antibody-13 or digoxin antibody-14) at room temperature for 3 minutes; the amplified PCR products labeled with FITC were incubated with FITC antibodies at room temperature for 3 minutes (wherein the digoxin antibody and FITC antibody were prepared by Example 4). Finally, the incubated reactants were subjected to agarose gel electrophoresis to identify the binding efficiency of the antibody and the labeled PCR product. The identification results are shown in the figure. Figure 5 shown.

[0139] Depend on Figure 5It can be seen that the PCR amplification products in lanes 4 and 5 can produce multimers with digoxigenin antibody, and the multimer band produced in lane 5 is brighter, which indicates that digoxigenin antibody-13 can produce multimers with PCR amplification products and its efficiency is higher than that of other lanes. Therefore, digoxigenin was selected as the primer marker and digoxigenin antibody-13 as the subsequent labeling antibody.

[0140] Table 8 Pseudomonas aeruginosa PCR amplification primer pair sequence

[0141] Primer name Sequence 5'-3' SEQ ID NO. PA-lasB-F3 GCAAGACCGAGAATGACAAAGTGGAACTGGTGATC 13 PA-lasB-R3 ATCGAGCACTTCGCCGGTCTTGGCGTCGATG 14

[0142] Example 6 Selection of biotin and digoxigenin labeling concentrations

[0143] In this example, Pseudomonas aeruginosa was used as an example to screen the concentrations of biotin and digoxigenin labels (the primers and probe sequences used for amplification are shown in Table 8, and the 5' end of the reverse primer PA-lasB-R3 is labeled with Biotin). For the markers biotin and digoxigenin on the amplified product, they need to be combined with streptavidin (SA) and digoxigenin antibodies on the test strip later, and now it is necessary to screen the concentration ratio of biotin and digoxigenin antibodies. The remaining steps are consistent with the amplification detection method for detecting Klebsiella pneumoniae described in Example 1. The PCR products labeled with biotin and digoxigenin after PCR amplification were gradient screened with streptavidin (SA) and digoxigenin antibodies (DIG-13) according to the molar concentration ratio, and incubated at room temperature for 3 minutes, and then agarose gel electrophoresis was performed to identify the binding efficiency. The electrophoresis results are shown in FIG. Figure 6 shown.

[0144] Depend on Figure 6 It can be seen that for lanes 4 and 5, the PCR product can produce significant multimer binding with SA; for lane 8, the PCR product can produce significant multimer binding with DIG-13, indicating that the subsequent polymerized amplification of the signal value can be performed through the polymer. Therefore, the concentration of PCR amplification product: SA: DIG-13 = 1:1:1 was selected for the test strip detection.

[0145] Example 7 Sample Release Buffer Optimization

[0146] Direct testing of the sample with a test strip after RPA amplification will result in the test strip not being able to be imaged (because the amplified sample is viscous, which makes it impossible to perform capillary action and cannot be imaged on the test strip). Therefore, the sample release buffer is optimized. Select 1.5*10 5The nucleic acid of Klebsiella pneumoniae samples with a sample concentration of CFU / ml was extracted and RPA amplified (the primer probe combination used was SEQ ID NO: 2, 5 and 8), and water, PBS, and PBST+0.05% Triton solution were selected as sample release buffers for comparative detection tests. The results are shown in Figure 7 shown.

[0147] From the comparative test of different sample release buffers above, it can be seen that PBST+0.05% Triton solution can fully release the RPA amplified sample to obtain a more sensitive detection.

[0148] Example 8 Preparation of Test Strips

[0149] 1. Preparation of labeled microspheres

[0150] Take two tubes of 200 μl of 200 nm blue microspheres (Jiaxing Maijin Biotechnology Co., Ltd.), add 1400 μl of activation buffer (HEPES solution 5.6 g / L pH 7.45), blow and mix; add 0.2mg streptavidin (SA) solution to the first tube of microsphere 1, and add mouse anti-human antibody (0.2mg, Merck, catalog number: I6760) to the second tube of microsphere 2; add 1mg / mL EDC (1-ethyl-(3-dimethylaminopropyl) carbodiimide) to the tube wall, quickly shake up and down to mix, and place in a constant temperature reaction for 60mins (24℃, 100rpm); after the reaction, ultrasonicate each tube 5 times, add 100μl of blocking agent (CE510 solution), ultrasonicate again 5 times, and continue to place in a constant temperature shaker for blocking for 90mins (100rpm, 24℃); after blocking, centrifuge for 20min (13000rpm, 4℃), discard the supernatant, and resuspend the precipitate with 2ml PBS storage buffer; store in a 2-8℃ refrigerator for later use.

[0151] 2. Gold coating on test strips

[0152] The two tubes of labeled microsphere solutions prepared above were diluted 20 times with PBS solution, and then the microsphere 1 was sprayed with gold at a concentration of 6 μl / cm, and then dried in a dryer; then the microsphere 2 was sprayed with gold and dried. Digoxin antibody (DIG-13) was sprayed on the nitrocellulose membrane using a film spray gold instrument as the test line (T line) and goat anti-mouse antibody (Sigma, catalog number: A9309-1mL) as the quality control line (C line).

[0153] Take 15μl of the amplified product and add it to 75μl of sample buffer, vortex and mix, then add it to the processed test strip, and wait for about 3 minutes to determine whether it is positive or negative. When both the test line (T line) and the quality control line (C line) of the test strip have bands, it means that the result is positive and Klebsiella pneumoniae exists; if only the quality control line has a band and there is no band at the test line, it means that the result is negative and Klebsiella pneumoniae does not exist; if no band appears on the quality control line, the result is invalid.

[0154] Example 9 Sample-specific test strip detection

[0155] Specific detection was performed on samples of different strains. The samples were: Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Pseudomonas putida, Escherichia coli, Rhizopus oryzae, NC, and the above different strain types are common strains. The remaining steps are consistent with the RPA detection method for detecting Klebsiella pneumoniae described in Example 3. RPA amplification verification was performed on the extracted DNA of different samples (the primer probe combination used was SEQ ID NO: 2, 5 and 8), and the results are as follows Figure 8 shown.

[0156] Depend on Figure 8 It can be seen that the primer-probe combination of the present invention can specifically detect Klebsiella pneumoniae samples and is exclusive and specific to Klebsiella pneumoniae samples.

[0157] Example 10 Sample sensitivity test strip detection

[0158] Sterile saline was used to dilute the Klebsiella pneumoniae strain sample in a gradient manner, and different concentrations (1:1.5*10 7 CFU / ml, 2:1.5*10 6 CFU / ml, 3:1.5*10 5 CFU / ml, 4:1.5*10 4 CFU / ml, 5:1.5*10 3 CFU / ml, 6:1.5*10 2 CFU / ml) samples were tested for sensitivity. The remaining steps were consistent with the RPA detection method for Klebsiella pneumoniae described in Example 3. The extracted Klebsiella pneumoniae sample DNA was subjected to RPA amplification verification (the primer probe combination used was SEQ ID NO: 2, 5 and 8), and the results were as follows: Fig. 9 shown.

[0159] Depend on Fig. 9 It can be seen that the primer pair provided by the present invention has a sample concentration of 1.5*10 3CFU / ml, it can still be significantly detected. This proves that the primer-probe combination of the present invention has high sensitivity. And from the trend of the band depth, it can be seen that the lower the sample concentration, the lighter the positive band, so the concentration of the strain in the sample can be seen from the depth of the positive band.

[0160] Example 11 Microbial Species Identification System

[0161] System 61 for identification of microbial species: information collection module 51, identification module 52 and data storage module 53 (see Fig.10 ).

[0162] The information collection module 51 is used to collect the test strip results and identify the uploaded result pictures;

[0163] The identification module 52 is used to determine whether the sample to be identified is Klebsiella pneumoniae, and automatically upload and save the data. The judgment criteria for the identification are:

[0164] a. If there is no quality control line C, the identification result is considered invalid; if there is a quality control line C, proceed to step b;

[0165] b. If there is a T line, the result is considered positive for Klebsiella pneumoniae; if there is no T line, the result is considered negative for Klebsiella pneumoniae;

[0166] The data storage module 53 is used to store information, including user information, detection time and / or judgment results, to facilitate the subsequent recording and tracking of pathogen infection information.

[0167] Embodiment 12 Electronic device

[0168] This embodiment provides an electronic device, which can be expressed in the form of a computing device (for example, a server device), including a memory, a processor, and a computer program stored in the memory and executable on the processor, wherein the microbial species identification system of Embodiment 11 of the present invention can be implemented when the processor executes the computer program.

[0169] Fig.11 The hardware structure diagram of this embodiment is shown, and the electronic device 9 specifically includes:

[0170] At least one processor 91, at least one memory 92, and a bus 93 for connecting different system components (including the processor 91 and the memory 92), wherein:

[0171] The bus 93 includes a data bus, an address bus, and a control bus.

[0172] The memory 92 includes a volatile memory, such as a random access memory (RAM) 921 and / or a cache memory 922 , and may further include a read-only memory (ROM) 923 .

[0173] The memory 92 also includes a program tool 925 having a set (at least one) of program modules 924, such program modules 924 including but not limited to: an operating system, one or more application programs, other program modules and program data, each of which or some combination may include the implementation of a network environment.

[0174] The processor 91 executes various functional applications and data processing by running the computer programs stored in the memory 92, such as processing the sequence information in the sample and the sequence information in the database.

[0175] The electronic device 9 can further communicate with one or more external devices 94 (e.g., keyboards, pointing devices, etc.). Such communication can be performed through an input / output (I / O) interface 95. In addition, the electronic device 9 can also communicate with one or more networks (e.g., local area networks (LANs), wide area networks (WANs), and / or public networks, such as the Internet) through a network adapter 96. The network adapter 96 communicates with other modules of the electronic device 9 through a bus 93. It should be understood that, although not shown in the figure, other hardware and / or software modules can be used in conjunction with the electronic device 9, including but not limited to: microcode, device drivers, redundant processors, external disk drive arrays, RAID (disk array) systems, tape drives, and data backup storage systems, etc.

[0176] It should be noted that although several units / modules or sub-units / modules of the electronic device are mentioned in the above detailed description, this division is merely exemplary and not mandatory. In fact, according to the embodiments of the present application, the features and functions of two or more units / modules described above can be embodied in one unit / module. Conversely, the features and functions of one unit / module described above can be further divided into multiple units / modules to be embodied.

[0177] Embodiment 13 Computer readable storage medium

[0178] An embodiment of the present invention provides a computer-readable storage medium having a computer program stored thereon, and when the program is executed by a processor, the steps of the microbial species identification system of embodiment 11 of the present invention are implemented.

[0179] The readable storage medium may include but is not limited to: a portable disk, a hard disk, a random access memory, a read-only memory, an erasable programmable read-only memory, an optical storage device, a magnetic storage device or any suitable combination of the above.

[0180] In a possible implementation manner, the present invention may also be implemented in the form of a program product, which includes program codes. When the program product is run on a terminal device, the program codes are used to enable the terminal device to execute the steps of implementing the above-mentioned identification method.

[0181] The program code for executing the present invention may be written in any combination of one or more programming languages, and may be executed entirely on a user device, partially on a user device, as an independent software package, partially on a user device and partially on a remote device, or entirely on a remote device.

Claims

1. A primer pair for specific amplification of Klebsiella pneumoniae, the primer pair comprising a forward primer and a reverse primer, characterized in that: The nucleotide sequence of the forward primer is shown in any one of SEQ ID NOs: 1-3, and the nucleotide sequence of the reverse primer is shown in any one of SEQ ID NOs: 4-6; Preferably, the nucleotide sequence of the forward primer is as shown in SEQ ID NO:1, and the nucleotide sequence of the reverse primer is as shown in SEQ ID NO:5; or, the nucleotide sequence of the forward primer is as shown in SEQ ID NO:2, and the nucleotide sequence of the reverse primer is as shown in SEQ ID NO:4; or, the nucleotide sequence of the forward primer is as shown in SEQ ID NO:2, and the nucleotide sequence of the reverse primer is as shown in SEQ ID NO:5; or, the nucleotide sequence of the forward primer is as shown in SEQ ID NO:3, and the nucleotide sequence of the reverse primer is as shown in SEQ ID NO:5; and / or, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.

2. A gene probe coupled with digoxigenin labeling, characterized in that: The nucleotide sequence of the gene probe is shown in SEQ ID NO:

8.

3. A primer-probe combination, characterized in that: The primer-probe combination comprises the primer pair according to claim 1 and / or the gene probe according to claim 2; Preferably, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is as shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is as shown in SEQ ID NO:4, and a gene probe whose nucleotide sequence is as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is as shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is as shown in SEQ ID NO:5, and a gene probe whose nucleotide sequence is as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is as shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is as shown in SEQ ID NO:6, and a gene probe whose nucleotide sequence is as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is as shown in SEQ ID NO:2 and whose nucleotide sequence of the reverse primer is as shown in SEQ ID NO:4, and a gene probe whose nucleotide sequence is as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is as shown in SEQ ID NO:2 and whose nucleotide sequence of the reverse primer is as shown in SEQ ID NO:4 NO:5, and a gene probe with a nucleotide sequence as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair with a nucleotide sequence of a forward primer as shown in SEQ ID NO:2 and a nucleotide sequence of a reverse primer as shown in SEQ ID NO:6, and a gene probe with a nucleotide sequence as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair with a nucleotide sequence of a forward primer as shown in SEQ ID NO:3 and a nucleotide sequence of a reverse primer as shown in SEQ ID NO:4, and a gene probe with a nucleotide sequence as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair with a nucleotide sequence of a forward primer as shown in SEQ ID NO:3 and a nucleotide sequence of a reverse primer as shown in SEQ ID NO:5, and a gene probe with a nucleotide sequence as shown in SEQ ID NO:8; or, the primer-probe combination comprises a primer pair with a nucleotide sequence of a forward primer as shown in SEQ ID NO:3 and a nucleotide sequence of a reverse primer as shown in SEQ ID NO:6, and a gene probe with a nucleotide sequence as shown in SEQ ID NO:8; More preferably, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.

4. A test strip comprising a sample pad, a conjugate pad, a nitrocellulose membrane and an absorption pad, characterized in that: The conjugate pad comprises microsphere solution 1 and microsphere solution 2; the nitrocellulose membrane comprises a detection line T line and a quality control line C line; The microsphere solution 1 contains microspheres labeled with streptavidin; the microsphere solution 2 contains microspheres labeled with mouse anti-human antibody; the detection line T contains digoxigenin antibody, and the quality control line C contains goat anti-mouse antibody; Preferably, the test strip meets one or more of the following conditions: (1) The particle size of the microspheres is 100-300 nm, for example, 200 nm; (2) the molar concentration ratio of streptavidin in the microsphere solution 1 to the digoxigenin antibody in the detection line T is 1:1; and, (3) The binding pad is a colloidal gold binding pad, and the amount of gold sprayed onto the microspheres is, for example, 6 μl / cm.

5. Use of the primer pair as claimed in claim 1, the gene probe as claimed in claim 2, the primer-probe combination as claimed in claim 3 and / or the test strip as claimed in claim 4 in the preparation of a test kit for identifying Klebsiella pneumoniae.

6. A kit for identifying Klebsiella pneumoniae, characterized in that: The kit comprises one or more selected from the group consisting of the primer pair as claimed in claim 1, the gene probe as claimed in claim 2, the primer-probe combination as claimed in claim 3, and the test strip as claimed in claim 4; Preferably, the kit further comprises a nucleic acid extraction reagent and / or a sample release buffer; the nucleic acid extraction reagent is an alkaline reagent, and the sample release buffer comprises a phosphate buffered saline solution; More preferably, the nucleic acid extraction reagent is KOH and / or the sample release buffer is PBST+0.05% Triton.

7. A method for identifying Klebsiella pneumoniae in a sample for non-diagnostic purposes, characterized in that: The method comprises using the primer pair as claimed in claim 1, the gene probe as claimed in claim 2, the primer-probe combination as claimed in claim 3, the test strip as claimed in claim 4 and / or the kit as claimed in claim 6; Preferably, the method comprises the following steps: (I) performing RPA amplification on the DNA extracted from the sample to be tested using the primer pair according to claim 1, the gene probe according to claim 2, and / or the primer-probe combination according to claim 3 to obtain an RPA amplification product; and, (II) mixing the RPA amplification product and the sample release buffer in a volume ratio of 1:5, and adding the mixture to the test strip as claimed in claim 4; More preferably, the method further comprises: (III) determining whether Klebsiella pneumoniae is present in the sample to be tested based on the information on the test strip obtained after implementing step (II); The judgment conditions are: when the test strip has a detection line T line and a quality control line C line, it means that the result is positive and Klebsiella pneumoniae is present in the sample to be tested; when the test strip has only a quality control line C line but no detection line T line, it means that the result is negative and Klebsiella pneumoniae is not present in the sample to be tested; when the test strip has no quality control line C line, the result is invalid.

8. A Klebsiella pneumoniae identification system, characterized in that: The identification system comprises: (1) an information collection module: used to collect information on the test strip obtained by using the method according to claim 7; and, (2) Identification module: used to determine whether the sample to be tested contains Klebsiella pneumoniae; the judgment criteria are: a. If there is no quality control line C, the identification result is considered invalid; if there is a quality control line C, proceed to step b; b. If there is a T line, it is judged as positive for Klebsiella pneumoniae; if there is no T line, it is judged as negative for Klebsiella pneumoniae; (3) Data storage module: used to store user information, detection time, judgment results and other information.

9. A computer-readable storage medium having a computer program stored thereon, characterized in that: The computer program implements the authentication system according to claim 8.

10. An electronic device comprising a memory, a processor, and a computer program stored in the memory and executable on the processor, characterized in that: When the processor executes the computer program, the authentication system according to claim 8 is implemented.

11. Use of the primer pair according to claim 1, the gene probe according to claim 2, the primer-probe combination according to claim 3, the test strip according to claim 4, the kit according to claim 6, the identification system according to claim 8, the computer-readable storage medium according to claim 9 and / or the electronic device according to claim 10 in identifying whether a sample contains Klebsiella pneumoniae; Preferably, the use is for non-diagnostic purposes.